Eliem Therapeutics (ELYM) Competitors $2.44 +0.21 (+9.42%) As of 09/3/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ELYM vs. ACB, SCPH, GLUE, AVIR, NGNE, RNAC, NMRA, MREO, LFCR, and TVRDShould you be buying Eliem Therapeutics stock or one of its competitors? The main competitors of Eliem Therapeutics include Aurora Cannabis (ACB), scPharmaceuticals (SCPH), Monte Rosa Therapeutics (GLUE), Atea Pharmaceuticals (AVIR), Neurogene (NGNE), Cartesian Therapeutics (RNAC), Neumora Therapeutics (NMRA), Mereo BioPharma Group (MREO), Lifecore Biomedical (LFCR), and Tvardi Therapeutics (TVRD). These companies are all part of the "pharmaceutical products" industry. Eliem Therapeutics vs. Its Competitors Aurora Cannabis scPharmaceuticals Monte Rosa Therapeutics Atea Pharmaceuticals Neurogene Cartesian Therapeutics Neumora Therapeutics Mereo BioPharma Group Lifecore Biomedical Tvardi Therapeutics Eliem Therapeutics (NASDAQ:ELYM) and Aurora Cannabis (NASDAQ:ACB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk. Which has more risk & volatility, ELYM or ACB? Eliem Therapeutics has a beta of -0.39, indicating that its stock price is 139% less volatile than the S&P 500. Comparatively, Aurora Cannabis has a beta of 1.91, indicating that its stock price is 91% more volatile than the S&P 500. Do insiders and institutionals have more ownership in ELYM or ACB? 69.8% of Eliem Therapeutics shares are held by institutional investors. Comparatively, 47.6% of Aurora Cannabis shares are held by institutional investors. 4.7% of Eliem Therapeutics shares are held by company insiders. Comparatively, 0.0% of Aurora Cannabis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has better earnings & valuation, ELYM or ACB? Aurora Cannabis has higher revenue and earnings than Eliem Therapeutics. Aurora Cannabis is trading at a lower price-to-earnings ratio than Eliem Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEliem TherapeuticsN/AN/A-$35.12M-$0.53-4.60Aurora Cannabis$246.72M1.11$1.63M-$0.19-25.42 Does the media prefer ELYM or ACB? In the previous week, Aurora Cannabis had 1 more articles in the media than Eliem Therapeutics. MarketBeat recorded 1 mentions for Aurora Cannabis and 0 mentions for Eliem Therapeutics. Eliem Therapeutics' average media sentiment score of 0.00 equaled Aurora Cannabis'average media sentiment score. Company Overall Sentiment Eliem Therapeutics Neutral Aurora Cannabis Neutral Do analysts prefer ELYM or ACB? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Aurora Cannabis 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.00 Is ELYM or ACB more profitable? Eliem Therapeutics has a net margin of 0.00% compared to Aurora Cannabis' net margin of -5.66%. Aurora Cannabis' return on equity of -1.49% beat Eliem Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Eliem TherapeuticsN/A -47.03% -45.97% Aurora Cannabis -5.66%-1.49%-1.06% SummaryAurora Cannabis beats Eliem Therapeutics on 10 of the 14 factors compared between the two stocks. Get Eliem Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELYM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ELYM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELYM vs. The Competition Export to ExcelMetricEliem TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$72.60M$822.15M$5.76B$9.85BDividend YieldN/A4.84%6.67%4.51%P/E Ratio-4.601.0975.7826.43Price / SalesN/A26.59546.96119.09Price / CashN/A19.5637.0558.92Price / Book0.636.6411.146.06Net Income-$35.12M-$4.78M$3.29B$266.28M7 Day Performance6.09%1.53%0.16%-0.32%1 Month Performance43.53%12.43%6.26%3.44%1 Year Performance-67.77%29.37%54.63%23.11% Eliem Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELYMEliem TherapeuticsN/A$2.44+9.4%N/A-66.3%$72.60MN/A-4.609ACBAurora Cannabis0.1491 of 5 stars$5.26+0.5%N/A-14.8%$294.95M$246.72M-27.501,130SCPHscPharmaceuticals4.1147 of 5 stars$5.53+0.1%$12.00+117.2%+9.6%$294.48M$36.33M-3.0530Short Interest ↑High Trading VolumeGLUEMonte Rosa Therapeutics2.775 of 5 stars$4.68+1.9%$15.33+228.0%-12.8%$289.04M$75.62M13.0090News CoverageGap UpAVIRAtea Pharmaceuticals2.6156 of 5 stars$3.62-1.2%$6.00+66.0%-8.3%$286.88MN/A-2.2570Positive NewsNGNENeurogene2.368 of 5 stars$20.11+0.6%$46.17+129.6%-43.2%$286.54M$930K-4.6690Positive NewsRNACCartesian Therapeutics2.2142 of 5 stars$10.83-3.8%$40.00+269.5%-25.7%$281.45M$38.91M-0.2064News CoveragePositive NewsNMRANeumora Therapeutics3.2163 of 5 stars$1.74+6.4%$7.14+311.7%-85.2%$280.98MN/A-1.11108Short Interest ↓MREOMereo BioPharma Group2.4924 of 5 stars$1.75+0.3%$7.40+324.1%-60.2%$279.05M$10M-25.0740LFCRLifecore Biomedical0.7027 of 5 stars$7.45-1.8%$8.00+7.4%+88.2%$278.70M$128.87M-5.69690News CoverageAnalyst ForecastTVRDTvardi TherapeuticsN/A$29.16-0.1%$64.25+120.3%N/A$273.43MN/A0.0080Positive News Related Companies and Tools Related Companies Aurora Cannabis Alternatives scPharmaceuticals Alternatives Monte Rosa Therapeutics Alternatives Atea Pharmaceuticals Alternatives Neurogene Alternatives Cartesian Therapeutics Alternatives Neumora Therapeutics Alternatives Mereo BioPharma Group Alternatives Lifecore Biomedical Alternatives Tvardi Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELYM) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eliem Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eliem Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
